Why is the mortality rate of pancreatic cancer is soo high?

The pancreas is an oblong organ located deep in the abdomen that serves two critical roles — it secretes hormones to regulate the body and produces digestive enzymes to break down food. When cancer develops in the pancreas, it most commonly takes the form of an exocrine tumor, with adenocarcinoma being the most prevalent type. Adenocarcinoma begins in the glandular cells lining the pancreatic duct and is significantly more aggressive than the less common endocrine tumors, known as neuroendocrine tumors. According to the National Cancer Institute, pancreatic cancer can generally only be controlled through surgical removal, and only when it is caught before it has spread.

The core reason pancreatic cancer is so deadly is that it rarely produces symptoms in its early stages. By the time patients experience warning signs such as abdominal pain or jaundice, the disease has typically already reached an advanced stage. Studies also suggest that the onset of diabetes after the age of 50 may serve as an early indicator of pancreatic cancer — a connection that is still being actively researched. As people age, the risk of developing the disease increases, and certain groups face a higher baseline risk, including men, African Americans, and individuals who smoke.

Pancreatic cancer is the third leading cause of cancer death in the United States, after lung cancer and colorectal cancer. The American Cancer Society estimates that approximately 55,440 people are diagnosed with the disease each year, resulting in around 44,330 deaths — with roughly 95% of patients ultimately dying from the disease. The five-year survival rate for adenocarcinoma remains below 5%, compared to 50–80% for the rarer neuroendocrine tumors, which can sometimes be benign.

Beyond age, sex, and race, certain inherited genetic conditions also elevate risk. Two rare genetic syndromes — Multiple Endocrine Neoplasia type 1 (MEN1) and Von Hippel-Lindau syndrome (VHL) — are known to increase susceptibility to pancreatic neuroendocrine tumors specifically. For patients whose cancer has already spread at the time of diagnosis, treatment focuses on palliative care to preserve quality of life rather than cure. These statistics underscore the urgent need for better early detection tools and more effective therapies for this devastating disease.